Identical to kai-9531 solution for injection without active drug
Sponsors
Kailera Therapeutics Inc.
Conditions
Obesity
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes
Not yet recruitingCTIS2025-523510-87-00
Target: 37Updated: 2026-05-04
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes
Not yet recruitingCTIS2025-523486-17-00
Target: 79Updated: 2026-05-05